Natera and Kupando Therapeutics Partner for Phase I Trial of KUP-101 in Advanced Skin Cancers

Natera, Inc. is partnering with Kupando Therapeutics for a Phase 1 clinical trial assessing circulating tumor DNA (ctDNA) dynamics with Latitude in advanced skin cancers.